Cellectis to post Q1 2026 results on May 11

Cellectis S.A. filed a Form 6-K announcing it will release first quarter 2026 financial results, for the period ending March 31, 2026, on May 11, 2026 after the close of the U.S. market.

Rhea-AI Filing Summary

Cellectis S.A. filed a Form 6-K announcing it will release first quarter 2026 financial results, for the period ending March 31, 2026, on May 11, 2026 after the close of the U.S. market. The release will be posted in the Investors section of its website and no conference call will be held.

The filing also reiterates that Cellectis is a clinical-stage biotechnology company using its gene-editing platform to develop allogeneic CAR T immunotherapies and other cell and gene therapies, with headquarters in Paris and additional locations in New York and Raleigh.

Key Terms

Form 6-K, foreign private issuer, gene-editing platform, allogeneic, +1 more

5 terms

Form 6-K regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

gene-editing platform financial

"a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies"

allogeneic technical

"The company utilizes an allogeneic approach for CAR T immunotherapies in oncology"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

CAR T immunotherapies medical

"an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cellectis (CLLS) report its first quarter 2026 financial results?

Cellectis will report its first quarter 2026 financial results on May 11, 2026 after the close of the U.S. market. The results will cover the quarter ending March 31, 2026 and will be published in the Investors section of the company’s website.

Will Cellectis (CLLS) host a conference call for its Q1 2026 results?

Cellectis will not host a conference call to discuss its first quarter 2026 financial results. Instead, investors can access the press release on the company’s website and contact the investor relations team directly via the investors@cellectis.com email address for any follow-up questions.

Where can investors find Cellectis’ Q1 2026 earnings press release?

Investors can find Cellectis’ Q1 2026 earnings press release in the Investors section of the company’s website, under press releases. The Form 6-K states that the financial results for the quarter ending March 31, 2026 will be posted there after the market close.

What type of company is Cellectis (CLLS) according to this filing?

Cellectis is described as a clinical-stage biotechnology company using a pioneering gene-editing platform to develop life-saving cell and gene therapies. It focuses on allogeneic CAR T immunotherapies in oncology and gene therapies in other indications, with in-house manufacturing capabilities across the value chain.

On which stock exchanges is Cellectis (CLLS) listed?

Cellectis is listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS. These listings allow the company’s shares to trade in both U.S. and European markets, as highlighted in the company description section of the announcement.

How can investors and media contact Cellectis regarding this Q1 2026 update?

Investors can contact Cellectis via the dedicated email investors@cellectis.com, addressed to the Chief Financial Officer and Chief Business Officer. Media inquiries can be directed to the listed communications contacts by email or phone, as detailed in the announcement’s contact section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:35 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 4, 2026

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

Exhibit		Title
99.1		Press release, dated May 4, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Cellectis S.A.
		(Registrant)
Date: May 4, 2026		/s/ André Choulika
		André Choulika
		Chief Executive Officer

EXHIBIT 99.1

Cellectis to Report First Quarter Financial Results on May 11, 2026

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after the close of the US market.

The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/

Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• PRESS RELEASE_Q1 earnings announcement (https://ml.globenewswire.com/Resource/Download/53c9c027-325f-48f3-a4aa-505a0b7c0706)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 3.1 KB